Latest Capital Raising News

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

PYC Therapeutics has successfully closed a $537 million institutional placement and entitlement offer, positioning the company to raise at least $600 million to advance its RNA-based therapies targeting genetic diseases.

Patagonia Lithium Ltd has successfully raised A$2.9 million through a private placement, aiming to fast-track drilling and feasibility studies at its flagship Formentera Project in Argentina.

Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.

Bellavista Resources has successfully raised A$35 million through a two-tranche placement to fund its strategic acquisition and exploration plans in Canada and Australia.

Strickland Metals has successfully raised A$55 million through an institutional placement to accelerate exploration and advance a Pre-Feasibility Study at its Rogozna Project in Serbia.

5E Advanced Materials has successfully closed an oversubscribed US$36 million public offering, positioning itself to advance its boron operations and finalise key commercial contracts.

Leeuwin Metals has reported promising high-grade gold assay results from its 2026 drilling campaign at the Evanston prospect within the Marda Gold Project, signalling potential resource expansion.

AuKing Mining Ltd has kicked off a $2 million share placement with a first tranche completed and seeks shareholder approval for the second. The company also plans a fresh marketing partnership with Singapore’s Bullseye Analytics, issuing options as part of the deal.

Strickland Metals has announced a $55 million institutional placement to fund an expanded drilling program and advance a Pre-Feasibility Study for its Rogozna gold project in Serbia, with major shareholders reaffirming their support.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.